Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
RenovoRx, Inc. (RNXT)
USD0.86
+0.01 (+1.13%)
US NASDAQ Healthcare Biotechnology
Address
4546 El Camino Real 94022
Mountain View, CA, US
Mountain View, CA, US
CEO
Shaun R. Bagai
Website
renovorx.com
IPO
2021-08-26
CIK 1574094 ISIN US75989R1077
Description
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.86
+0.01 (+1.13%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
292.6K
Beta
0.99
Float Shares
33.85M
Free Float %
96.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.77% | -6.91% | -16.80% | -9.08% | -12.91% | +1.01% | -17.61% | -61.95% | -88.31% | -88.31% | -88.31% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
0.86
DCF (Unlevered)
0.94
+9.0%
DCF (Levered)
0.37
-57.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-7.60
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+2,511.6% ★ Q1'26: +185.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+13.5% Q1'26: -16.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,136.0% Q1'26: -647.1% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-1,114.1% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+49.7% Q1'26: +21.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
43.0K
est: 662.0K (-93.5%)
|
1.12M
est: 1.30M (-13.9%)
|
3.25M
2.77M – 3.71M
+148.9% YoY
|
12.32M
4.01M – 20.62M
+279.3% YoY
|
38.28M
17.02M – 62.95M
+210.7% YoY
|
123.45M
54.90M – 203.02M
+222.5% YoY
|
259.30M
115.32M – 426.44M
+110.1% YoY
|
| EBITDA |
-10.97M
est: 132.4K (-8,385.6%)
|
-12.51M
est: 260.9K (-4,894.2%)
|
649.6K
554.8K – 742.4K
+148.9% YoY
|
2.46M
802.3K – 4.12M
+279.3% YoY
|
7.66M
3.40M – 12.59M
+210.7% YoY
|
24.69M
10.98M – 40.60M
+222.5% YoY
|
51.86M
23.06M – 85.29M
+110.1% YoY
|
| EBIT |
-10.97M
est: 132.4K (-8,385.6%)
|
-12.51M
est: 260.9K (-4,894.6%)
|
649.6K
554.8K – 742.4K
+148.9% YoY
|
2.46M
802.3K – 4.12M
+279.3% YoY
|
7.66M
3.40M – 12.59M
+210.7% YoY
|
24.69M
10.98M – 40.60M
+222.5% YoY
|
51.86M
23.06M – 85.29M
+110.1% YoY
|
| Net Income |
-8.81M
est: -10.66M (+17.3%)
|
-11.17M
est: -6.99M (-59.7%)
|
-9.82M
-11.27M – -8.37M
-40.4% YoY
|
-6.67M
-8.60M – -1.30M
+32.1% YoY
|
5.83M
-6.01M – 8.13M
+187.4% YoY
|
23.44M
6.52M – 43.08M
+302.1% YoY
|
60.07M
16.71M – 110.40M
+156.3% YoY
|
| SGA |
4.99M
est: 16.59M (-69.9%)
|
7.04M
est: 32.69M (-78.5%)
|
81.37M
69.50M – 93.00M
+148.9% YoY
|
308.66M
100.51M – 516.60M
+279.3% YoY
|
959.01M
426.50M – 1.58B
+210.7% YoY
|
3.09B
1.38B – 5.09B
+222.5% YoY
|
6.50B
2.89B – 10.68B
+110.1% YoY
|
| EPS |
-0.37
est: -0.39 (+5.1%)
|
-0.32
est: -0.20 (-61.7%)
|
-0.28
-0.32 – -0.24
-42.7% YoY
|
-0.13
-0.24 – -0.04
+53.1% YoY
|
0.07
-0.17 – 0.23
+152.8% YoY
|
0.66
0.18 – 1.22
+847.6% YoY
|
1.70
0.47 – 3.12
+156.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-10.57M
OE per share TTM
-0.31
Owner's Yield
-35.25%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
42.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
11
Total invested
4.32M
Insider transactions (90d)
0
Beneficial owners (>5%)
4
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Najmabadi | 1.05M | 11.70% | 70.0K | 975.0K | 70.0K | 975.0K | IN | States | 2022-02-14 | ↗ |
| 2 | Non-Grantor Trust Dtd 01/19/2016 | 975.0K | 10.79% | 975.0K | — | — | — | BK | California | 2022-04-14 | ↗ |
| 3 | Najmabadi Family Trust dated April 22, 2021 | 731.3K | 8.20% | 731.3K | — | 731.3K | — | OO | California | 2022-02-14 | ↗ |
| 4 | Boston Scientific Corporation | 544.0K | 8.00% | 544.0K | — | 544.0K | — | CO | — | 2022-02-10 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
11
-22 vs prev Q
New positions
1
Closed positions
23
Increased
4
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | AIGH CAPITAL MANAGEMENT LLC | 2.83M +218.7K (+8.4%) | 3.67M +349.8K (+10.5%) | 7.73% +0.583 pp | 0.89% -0.047 pp | USD0.98 -14.3% | 4 qtrs — |
| 2 | VANGUARD GROUP INC | 1.61M +— (+0.0%) | 1.35M -690.2K (-33.9%) | 4.38% -0.008 pp | 0.00% +0.000 pp | USD1.13 -25.7% | 16 qtrs — |
| 3 | BLEICHROEDER LP | 600.0K +61.4K (+11.4%) | 504.1K -180.0K (-26.3%) | 1.64% +0.165 pp | 0.09% -0.045 pp | USD0.99 -15.2% | 4 qtrs — |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 371.4K -91.0 (0.0%) | 312.0K -159.8K (-33.9%) | 1.01% -0.002 pp | 0.00% +0.000 pp | USD1.25 -32.8% | 14 qtrs — |
| 5 | WEALTHSPIRE ADVISORS, LLC | 252.5K +252.5K (+100.0%) | 212.1K +212.1K (+100.0%) | 0.69% +0.689 pp | 0.00% +0.002 pp | USD0.84 +0.0% | 1 qtrs NEW |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 117.5K -196.1K (-62.5%) | 98.7K -299.5K (-75.2%) | 0.32% -0.537 pp | 0.00% 0.000 pp | USD1.31 -35.9% | 7 qtrs — |
| 7 | CHICAGO PARTNERS INVESTMENT GROUP LLC | 92.4K +— (+0.0%) | 92.0K -12.4K (-11.9%) | 0.25% -0.001 pp | 0.00% -0.001 pp | USD0.99 -15.2% | 4 qtrs — |
| 8 | NIXON PEABODY TRUST CO | 97.2K +— (+0.0%) | 81.6K -41.8K (-33.9%) | 0.27% -0.001 pp | 0.01% -0.003 pp | USD2.29 -63.3% | 9 qtrs — |
| 9 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 90.0K +90.0K (+100.0%) | 75.6K +75.6K (+100.0%) | 0.25% +0.246 pp | 0.00% +0.000 pp | USD0.84 +0.0% | 1 qtrs NEW |
| 10 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 74.6K +20.0 (+0.0%) | 62.7K -32.1K (-33.8%) | 0.20% 0.000 pp | 0.00% +0.000 pp | USD1.32 -36.4% | 3 qtrs — |
| 11 | CAPROCK GROUP, LLC | 63.9K +63.9K (+100.0%) | 53.7K +53.7K (+100.0%) | 0.17% +0.175 pp | 0.00% +0.001 pp | USD0.84 +0.0% | 1 qtrs NEW |
| 12 | CITADEL ADVISORS LLC | 53.4K -67.9K (-56.0%) | 44.9K -109.2K (-70.9%) | 0.15% -0.186 pp | 0.00% +0.000 pp | USD1.27 -33.9% | 2 qtrs — |
| 13 | XTX TOPCO LTD | 50.1K +18.5K (+58.6%) | 42.1K +2.0K (+4.9%) | 0.14% +0.050 pp | 0.00% -0.001 pp | USD1.11 -24.3% | 5 qtrs — |
| 14 | NORTHERN TRUST CORP | 42.2K +— (+0.0%) | 35.4K -18.1K (-33.9%) | 0.12% 0.000 pp | 0.00% +0.000 pp | USD1.09 -22.9% | 4 qtrs — |
| 15 | KESTRA ADVISORY SERVICES, LLC | 35.5K +— (+0.0%) | 29.8K -15.3K (-33.9%) | 0.10% 0.000 pp | 0.00% 0.000 pp | USD1.06 -20.8% | 6 qtrs — |
| 16 | STATE STREET CORP | 26.2K +— (+0.0%) | 22.0K -11.2K (-33.9%) | 0.07% 0.000 pp | 0.00% +0.000 pp | USD1.28 -34.4% | 10 qtrs — |
| 17 | HIGHTOWER ADVISORS, LLC | 20.0K -20.0K (-50.0%) | 16.8K -34.0K (-66.9%) | 0.05% -0.055 pp | 0.00% +0.000 pp | USD0.99 -15.2% | 4 qtrs — |
| 18 | CYPRESS POINT WEALTH MANAGEMENT, LLC | 20.0K +20.0K (+100.0%) | 16.8K +16.8K (+100.0%) | 0.05% +0.055 pp | 0.00% +0.004 pp | USD0.84 +0.0% | 1 qtrs NEW |
| 19 | TWO SIGMA SECURITIES, LLC | 19.6K +19.6K (+100.0%) | 16.5K +16.5K (+100.0%) | 0.05% +0.054 pp | 0.00% +0.002 pp | USD0.84 +0.0% | 5 qtrs — |
| 20 | JANE STREET GROUP, LLC | 13.9K +146.0 (+1.1%) | 11.7K -5.8K (-33.1%) | 0.04% +0.000 pp | 0.00% +0.000 pp | USD1.27 -33.9% | 2 qtrs — |
| 21 | GROUND SWELL CAPITAL, LLC | 13.6K +13.6K (+100.0%) | 11.4K +11.4K (+100.0%) | 0.04% +0.037 pp | 0.02% +0.024 pp | USD0.84 +0.0% | 1 qtrs NEW |
| 22 | AFFINITY CAPITAL ADVISORS, LLC | 13.3K +— (+0.0%) | 11.2K -5.7K (-33.8%) | 0.04% 0.000 pp | 0.00% -0.001 pp | USD2.11 -60.2% | 14 qtrs — |
| 23 | CAPTRUST FINANCIAL ADVISORS | 12.3K +— (+0.0%) | 10.3K -5.3K (-33.9%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD1.32 -36.4% | 3 qtrs — |
| 24 | CETERA INVESTMENT ADVISERS | 11.0K +11.0K (+100.0%) | 9.2K +9.2K (+100.0%) | 0.03% +0.030 pp | 0.00% +0.000 pp | USD0.84 +0.0% | 1 qtrs NEW |
| 25 | COLONY GROUP, LLC | 11.0K +— (+0.0%) | 9.2K -4.7K (-33.9%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD0.99 -15.2% | 4 qtrs — |
| 26 | HRT FINANCIAL LP | 10.7K -14.0K (-56.7%) | 9.0K -22.0K (-71.0%) | 0.03% -0.039 pp | 0.00% 0.000 pp | USD1.31 -35.9% | 3 qtrs — |
| 27 | CAPITAL ADVISORS WEALTH MANAGEMENT, LLC | 10.0K +— (+0.0%) | 8.4K -4.3K (-33.9%) | 0.03% 0.000 pp | 0.00% -0.001 pp | USD1.32 -36.4% | 3 qtrs — |
| 28 | TOWER RESEARCH CAPITAL LLC (TRC) | 6.4K +4.8K (+300.4%) | 5.3K +3.3K (+164.9%) | 0.02% +0.013 pp | 0.00% +0.000 pp | USD0.95 -11.6% | 18 qtrs — |
| 29 | FNY INVESTMENT ADVISERS, LLC | 3.7K -12.3K (-76.9%) | 3.0K -17.0K (-85.0%) | 0.01% -0.034 pp | 0.00% -0.006 pp | USD1.27 -33.9% | 2 qtrs — |
| 30 | UBS GROUP AG | 2.3K +1.6K (+239.6%) | 1.9K +1.1K (+124.8%) | 0.01% +0.004 pp | 0.00% +0.000 pp | USD0.90 -6.7% | 7 qtrs — |
| 31 | MORGAN STANLEY | 1.1K +1.1K (+100.0%) | 942.00 +942.0 (+100.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD0.84 +0.0% | 1 qtrs NEW |
| 32 | BANK OF AMERICA CORP /DE/ | 306.00 +14.0 (+4.8%) | 257.00 -114.0 (-30.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.10 -23.6% | 9 qtrs — |
| 33 | CITIGROUP INC | 1.00 -3.1K (-100.0%) | 1.00 -3.9K (-100.0%) | 0.00% -0.008 pp | 0.00% +0.000 pp | USD1.00 -16.0% | 2 qtrs — |
| 34 | BARCLAYS PLC | — -118.0 (-100.0%) | — -150.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 35 | CORSAIR CAPITAL MANAGEMENT, L.P. | — -93.5K (-100.0%) | — -118.7K (-100.0%) | 0.00% -0.256 pp | 0.00% -0.020 pp | USD— | 4 qtrs SOLD |
| 36 | SBI SECURITIES CO., LTD. | — -2.0 (-100.0%) | — -3.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 37 | BRIGHTON JONES LLC | — -10.7K (-100.0%) | — -13.5K (-100.0%) | 0.00% -0.029 pp | 0.00% 0.000 pp | USD— | 4 qtrs SOLD |
| 38 | AWM INVESTMENT COMPANY, INC. | — -863.8K (-100.0%) | — -1.1M (-100.0%) | 0.00% -2.362 pp | 0.00% -0.103 pp | USD— | 4 qtrs SOLD |
| 39 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | — -49.2K (-100.0%) | — -62.5K (-100.0%) | 0.00% -0.135 pp | 0.00% +0.000 pp | USD— | 10 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 337.7K | 0.05% |
| 2 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 2.0K | 0.03% |
| 3 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 5.5K | 0.17% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 404.27 | 0.17% |
| 5 | Vanguard Total Stock Market ETF VTI | 0.00% | 935.2K | 0.03% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.0K | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.1K | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 450.73 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 49.68 | 0.22% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 6.99 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
8
Sells
0
Shares acquired
219.2K
Shares disposed
—
Cash buys
7.00
Cash sales
—
Net activity
+219,210
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-03 | VOLL MARK | Officer | A-Award | A | Common Stock | 80,000 | 0.00 | — | 117,380 | D | ↗ |
| 2026-04-03 | Gentry Leesa | Officer | A-Award | A | Stock Option | 128,550 | 0.98 | 126.0K | 128,550 | D | ↗ |
| 2026-04-03 | Bagai Shaun | Director / Officer | A-Award | A | Stock Option | 946,107 | 0.98 | 927.2K | 946,107 | D | ↗ |
| 2026-04-03 | Agah Ramtin | Director / Officer | A-Award | A | Stock Option | 621,727 | 0.98 | 609.3K | 621,727 | D | ↗ |
| 2026-03-25 | VOLL MARK | Officer | A-Award | A | Common Stock | 12,380 | 0.00 | — | 37,380 | D | ↗ |
| 2026-03-20 | VOLL MARK | Officer | P-Purchase | A | Common Stock | 97,200 | 0.00 | — | 97,200 | I | ↗ |
| 2026-03-20 | Marton Laurence | Director | P-Purchase | A | Common Stock | 9,720 | 0.00 | — | 9,720 | I | ↗ |
| 2026-03-20 | Bagai Shaun | Director / Officer | P-Purchase | A | Common Stock | 24,300 | 0.00 | — | 313,357 | I | ↗ |
| 2026-02-04 | VOLL MARK | Officer | — | — | Common Stock | 0 | 0.00 | — | 25,000 | D | ↗ |
| 2026-01-21 | Agah Ramtin | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 1.00 | 10.0K | 798,460 | D | ↗ |
| 2025-12-31 | Agah Ramtin | Director / Officer | P-Purchase | A | Common Stock | 9,795 | 0.86 | 8.4K | 788,460 | D | ↗ |
| 2025-12-30 | Agah Ramtin | Director / Officer | P-Purchase | A | Common Stock | 205 | 0.83 | 169.33 | 778,665 | D | ↗ |
| 2025-12-18 | Bagai Shaun | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 0.90 | 4.5K | 340,040 | D | ↗ |
| 2025-12-17 | Bagai Shaun | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 0.85 | 4.3K | 335,040 | D | ↗ |
| 2025-12-16 | Agah Ramtin | Director / Officer | P-Purchase | A | Common Stock | 12,000 | 0.85 | 10.2K | 778,460 | D | ↗ |
| 2025-12-05 | Agah Ramtin | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 0.96 | 9.6K | 766,460 | D | ↗ |
| 2025-11-24 | Agah Ramtin | Director / Officer | P-Purchase | A | Common Stock | 12,000 | 0.80 | 9.6K | 756,460 | D | ↗ |
| 2025-11-21 | Agah Ramtin | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 0.80 | 8.0K | 744,460 | D | ↗ |
| 2025-10-01 | Spiegel Robert J. | Director | A-Award | A | Stock Options (right to buy) | 47,640 | 1.34 | 63.8K | 47,640 | D | ↗ |
| 2025-10-01 | RYAN UNA S | Director | A-Award | A | Stock Options (right to buy) | 47,640 | 1.34 | 63.8K | 47,640 | D | ↗ |
| 2025-10-01 | Marton Laurence | Director | A-Award | A | Stock Options (right to buy) | 47,640 | 1.34 | 63.8K | 47,640 | D | ↗ |
| 2025-10-01 | Macfarlane K. Angela | Director | A-Award | A | Stock Options (right to buy) | 47,640 | 1.34 | 63.8K | 47,640 | D | ↗ |
| 2025-08-25 | Bagai Shaun | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 0.91 | 4.5K | 330,040 | D | ↗ |
| 2025-08-22 | Bagai Shaun | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 0.95 | 4.7K | 325,040 | D | ↗ |
| 2025-07-01 | Kocak Ron | Officer | A-Award | A | Stock Option | 41,600 | 1.27 | 52.8K | 41,600 | D | ↗ |
| 2025-07-01 | Gentry Leesa | Officer | A-Award | A | Stock Option | 6,619 | 1.27 | 8.4K | 6,619 | D | ↗ |
| 2025-07-01 | Bagai Shaun | Director / Officer | A-Award | A | Stock Option | 102,498 | 1.27 | 130.2K | 102,498 | D | ↗ |
| 2025-07-01 | Agah Ramtin | Director / Officer | A-Award | A | Stock Option | 63,636 | 1.27 | 80.8K | 63,636 | D | ↗ |
| 2025-06-05 | Agah Ramtin | Director / Officer | P-Purchase | A | Common Stock | 21,000 | 1.40 | 29.4K | 734,460 | D | ↗ |
| 2025-05-02 | Marton Laurence | Director | M-Exempt | A | Common Stock | 20,480 | 0.15 | 3.1K | 66,164 | D | ↗ |
| 2025-04-22 | Agah Ramtin | Director / Officer | G-Gift | D | Common Stock | 400,000 | 0.00 | — | 713,460 | D | ↗ |
| 2025-04-15 | Bagai Shaun | Director / Officer | P-Purchase | A | Common Stock | 7,500 | 0.91 | 6.8K | 320,040 | D | ↗ |
| 2025-04-15 | Agah Ramtin | Director / Officer | P-Purchase | A | Common Stock | 15,000 | 0.90 | 13.5K | 1,113,460 | D | ↗ |
| 2025-04-14 | Kocak Ron | Officer | A-Award | A | Stock Option | 166,400 | 0.84 | 140.6K | 166,400 | D | ↗ |
| 2025-04-14 | Gentry Leesa | Officer | A-Award | A | Stock Option | 26,477 | 0.84 | 22.4K | 26,477 | D | ↗ |
| 2025-04-14 | Bagai Shaun | Director / Officer | A-Award | A | Stock Option | 409,992 | 0.84 | 346.4K | 409,992 | D | ↗ |
| 2025-04-14 | Agah Ramtin | Director / Officer | A-Award | A | Stock Option | 254,542 | 0.84 | 215.0K | 254,542 | D | ↗ |
| 2025-04-11 | Agah Ramtin | Director / Officer | P-Purchase | A | Common Stock | 20,000 | 0.80 | 16.0K | 1,098,460 | D | ↗ |
| 2025-04-10 | Kocak Ron | Officer | P-Purchase | A | Common Stock | 6,500 | 0.79 | 5.1K | 12,595 | D | ↗ |
| 2025-04-09 | Kocak Ron | Officer | P-Purchase | A | Common Stock | 6,000 | 0.80 | 4.8K | 6,095 | D | ↗ |
| 2025-04-09 | Bagai Shaun | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 0.83 | 8.3K | 312,540 | D | ↗ |
| 2025-04-09 | Agah Ramtin | Director / Officer | P-Purchase | A | Common Stock | 30,000 | 0.81 | 24.4K | 1,078,460 | D | ↗ |
| 2025-04-08 | Marton Laurence | Director | P-Purchase | A | Common Stock | 12,050 | 0.85 | 10.2K | 45,684 | D | ↗ |
| 2025-04-08 | Kocak Ron | Officer | P-Purchase | A | Common Stock | 95 | 0.80 | 76.00 | 95 | D | ↗ |
| 2025-04-08 | Agah Ramtin | Director / Officer | P-Purchase | A | Common Stock | 26,000 | 0.84 | 21.8K | 1,048,460 | D | ↗ |
| 2025-04-07 | Bagai Shaun | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 0.83 | 8.3K | 302,540 | D | ↗ |
| 2024-10-01 | Spiegel Robert J. | Director | A-Award | A | Stock Options (right to buy) | 25,099 | 1.02 | 25.6K | 25,099 | D | ↗ |
| 2024-10-01 | RYAN UNA S | Director | A-Award | A | Stock Options (right to buy) | 25,099 | 1.02 | 25.6K | 25,099 | D | ↗ |
| 2024-10-01 | Marton Laurence | Director | A-Award | A | Stock Options (right to buy) | 25,099 | 1.02 | 25.6K | 25,099 | D | ↗ |
| 2024-10-01 | Macfarlane K. Angela | Director | A-Award | A | Stock Options (right to buy) | 25,099 | 1.02 | 25.6K | 25,099 | D | ↗ |
| 2024-03-06 | Gentry Leesa | Officer | A-Award | A | Options | 190,000 | 1.69 | 321.1K | 190,000 | — | ↗ |
| 2024-02-09 | Kocak Ron | Officer | A-Award | A | Options | 15,000 | 1.59 | 23.9K | 15,000 | — | ↗ |
| 2024-01-26 | Spiegel Robert J. | Director | P-Purchase | A | Common Stock | 40,983 | 1.22 | 50.0K | 40,983 | — | ↗ |
| 2024-01-26 | Marton Laurence | Director | P-Purchase | A | Common Stock | 8,196 | 1.22 | 10.0K | 33,634 | — | ↗ |
| 2024-01-26 | Macfarlane K. Angela | Director | P-Purchase | A | Common Stock | 40,983 | 1.22 | 50.0K | 40,983 | — | ↗ |
| 2024-01-26 | Bagai Shaun | Director / Officer | P-Purchase | A | Warrants | 40,983 | 1.22 | 50.0K | 40,983 | — | ↗ |
| 2024-01-26 | Agah Ramtin | Director / Officer | P-Purchase | A | Warrants | 40,983 | 1.22 | 50.0K | 40,983 | — | ↗ |
| 2024-01-19 | Nelms Angela | Officer | A-Award | A | Stock Option | 33,768 | 1.08 | 36.5K | 33,768 | — | ↗ |
| 2024-01-19 | Kocak Ron | Officer | — | D | Options | 48,128 | 1.08 | 52.0K | 0 | — | ↗ |
| 2024-01-19 | Gentry Leesa | Officer | — | D | Options | 60,159 | 1.08 | 65.0K | 0 | — | ↗ |
| 2024-01-19 | Bagai Shaun | Director / Officer | A-Award | A | Stock Option | 250,263 | 1.08 | 270.3K | 250,263 | — | ↗ |
| 2024-01-19 | Agah Ramtin | Director / Officer | A-Award | A | Stock Option | 125,132 | 1.08 | 135.1K | 125,132 | — | ↗ |
| 2023-10-03 | Nelms Angela | Officer | P-Purchase | A | Common Stock | 800 | 1.05 | 836.00 | 1,100 | — | ↗ |
| 2023-10-01 | Spiegel Robert J. | Director | A-Award | A | Stock Options (right to buy) | 25,099 | 1.33 | 33.4K | 25,099 | — | ↗ |
| 2023-10-01 | RYAN UNA S | Director | A-Award | A | Stock Options (right to buy) | 25,099 | 1.33 | 33.4K | 25,099 | — | ↗ |
| 2023-10-01 | Marton Laurence | Director | A-Award | A | Stock Options (right to buy) | 25,099 | 1.33 | 33.4K | 25,099 | — | ↗ |
| 2023-10-01 | Macfarlane K. Angela | Director | A-Award | A | Stock Options (right to buy) | 25,099 | 1.33 | 33.4K | 25,099 | — | ↗ |
| 2023-10-01 | Diamond David | Director | A-Award | A | Stock Options (right to buy) | 25,099 | 1.33 | 33.4K | 25,099 | — | ↗ |
| 2023-06-01 | Kocak Ron | Officer | — | D | Options | 3,000 | 2.11 | 6.3K | 0 | — | ↗ |
| 2023-06-01 | Gentry Leesa | Officer | — | D | Options | 62,500 | 2.11 | 131.9K | 0 | — | ↗ |
| 2023-04-25 | Spiegel Robert J. | Director | A-Award | A | Stock Option (right to buy) | 43,026 | 2.74 | 117.9K | 43,026 | — | ↗ |
| 2023-03-15 | Nelms Angela | Officer | A-Award | A | Employee Stock Option (right to buy) | 32,500 | 3.29 | 106.9K | 32,500 | — | ↗ |
| 2023-03-15 | Kocak Ron | Officer | — | D | Options | 15,875 | 3.29 | 52.2K | 0 | — | ↗ |
| 2023-03-15 | Bagai Shaun | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 130,000 | 3.29 | 427.7K | 130,000 | — | ↗ |
| 2023-03-15 | Agah Ramtin | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 65,000 | 3.29 | 213.9K | 65,000 | — | ↗ |
| 2022-11-03 | Marton Laurence | Director | M-Exempt | A | Common Stock | 25,438 | 1.70 | 43.2K | 25,438 | — | ↗ |
| 2022-10-01 | RYAN UNA S | Director | A-Award | A | Stock Option (right to buy) | 25,099 | 0.00 | — | 25,099 | — | ↗ |
| 2022-10-01 | Marton Laurence | Director | A-Award | A | Stock Option (right to buy) | 25,099 | 0.00 | — | 25,099 | — | ↗ |
| 2022-10-01 | Macfarlane K. Angela | Director | A-Award | A | Stock Option (right to buy) | 25,099 | 0.00 | — | 25,099 | — | ↗ |
| 2022-10-01 | Diamond David | Director | A-Award | A | Stock Option (right to buy) | 25,099 | 0.00 | — | 25,099 | — | ↗ |
| 2022-09-19 | Nelms Angela | Officer | A-Award | A | Employee Stock Option (right to buy) | 274,230 | 2.42 | 663.6K | 274,230 | — | ↗ |
| 2022-08-18 | Kocak Ron | Officer | — | D | Options | 34,390 | 2.19 | 75.3K | 0 | — | ↗ |
| 2022-07-15 | Ahlers James M | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-07 | Agah Ramtin | Officer | P-Purchase | A | Common Stock | 5,182 | 1.93 | 10.0K | 6,477 | — | ↗ |
| 2022-05-19 | Bagai Shaun | Officer | P-Purchase | A | Common Stock | 5,500 | 2.05 | 11.3K | 251,557 | — | ↗ |
| 2022-03-16 | BANK OF THE WEST | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 975,000 | — | ↗ |
| 2022-03-10 | RYAN UNA S | Director | A-Award | A | Stock Option (right to buy) | 4,582 | 3.17 | 14.5K | 4,582 | — | ↗ |
| 2022-03-10 | Marton Laurence | Director | A-Award | A | Stock Option (right to buy) | 4,582 | 0.00 | — | 4,582 | — | ↗ |
| 2022-03-10 | Macfarlane K. Angela | Director | A-Award | D | Stock option (right to buy) | 4,582 | 0.00 | — | 4,582 | — | ↗ |
| 2022-03-10 | Diamond David | Director | A-Award | A | Stock Option (right to buy) | 4,582 | 0.00 | — | 4,582 | — | ↗ |
| 2022-03-10 | Bagai Shaun | Officer | A-Award | A | Employee Stock Option (right to buy) | 48,313 | 0.00 | — | 48,313 | — | ↗ |
| 2022-03-10 | Agah Ramtin | Officer | A-Award | D | Employee Stock Option (right to buy) | 21,398 | 0.00 | — | 21,398 | — | ↗ |
| 2021-10-01 | RYAN UNA S | Director | A-Award | A | Stock Option (right to buy) | 11,154 | 5.91 | 65.9K | 11,154 | — | ↗ |
| 2021-10-01 | Marton Laurence | Director | A-Award | A | Stock Option (right to buy) | 11,154 | 5.91 | 65.9K | 11,154 | — | ↗ |
| 2021-10-01 | Macfarlane Kirsten Angela | Director | A-Award | A | Stock Option (right to buy) | 11,154 | 5.91 | 65.9K | 11,154 | — | ↗ |
| 2021-10-01 | Diamond David | Director | A-Award | A | Stock Option (right to buy) | 11,154 | 5.91 | 65.9K | 33,461 | — | ↗ |
| 2021-09-30 | Bagai Shaun | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 117,866 | 6.04 | 711.9K | 117,866 | — | ↗ |
| 2021-09-30 | Agah Ramtin | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 52,203 | 6.04 | 315.3K | 52,203 | — | ↗ |
| 2021-08-30 | Lehman Christopher John | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-08-30 | Agah Ramtin | Director / Officer / 10% Owner | C-Conversion | A | Common Stock | 1,295 | 10.80 | 14.0K | 976,295 | — | ↗ |
| 2021-08-25 | RYAN UNA S | Director | — | D | Stock Option (right to buy) | 16,000 | 0.65 | 10.4K | 0 | — | ↗ |
| 2021-08-25 | Najmabadi Kamran | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 121,875 | — | ↗ |
| 2021-08-25 | Marton Laurence | Director | — | D | Stock Option (right to buy) | 20,480 | 0.15 | 3.1K | 0 | — | ↗ |
| 2021-08-25 | Manners Paul | Officer | — | D | Stock Option (right to buy) | 4,666 | 0.70 | 3.3K | 0 | — | ↗ |
| 2021-08-25 | Macfarlane Kirsten Angela | Director | — | D | Stock Option (right to buy) | 32,000 | 0.65 | 20.8K | 0 | — | ↗ |
| 2021-08-25 | Diamond David | Director | — | D | Stock Option (right to buy) | 2,000 | 2.45 | 4.9K | 0 | — | ↗ |
| 2021-08-25 | Bagai Shaun | Director / Officer | — | D | Stock Option (right to buy) | 60,000 | 0.50 | 30.0K | 0 | — | ↗ |
| 2021-08-25 | Agah Ramtin | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 975,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-12.5K
Shares Outstanding
35.09M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Shaun R. Bagai Chief Executive Officer | 583.4K | 227.8K | — | 418.0K | — | 3.0K | 1.23M | 33.92% | ↗ |
| 2 | 2025 | Ramtin Agah, M.D. Chief Medical Officer | — | — | — | 259.5K | — | 432.7K | 692.2K | 37.49% | ↗ |
| 3 | 2025 | Ronald B. Kocak Vice President, Controller and Principal Accounting Officer | 346.1K | 85.7K | — | 169.7K | — | 15.2K | 616.7K | 27.51% | ↗ |
| 4 | 2024 | Shaun R. Bagai Chief Executive Officer | 520.0K | 400.5K | — | 259.2K | — | 46.4K | 1.23M | 21.14% | ↗ |
| 5 | 2024 | Leesa Gentry Chief Clinical Officer | 339.4K | 178.2K | — | 357.6K | — | 15.0K | 890.2K | 40.17% | ↗ |
| 6 | 2024 | Ramtin Agah, M.D. Chief Medical Officer | — | 170.0K | — | 129.6K | — | 303.5K | 603.0K | 21.49% | ↗ |
| 7 | 2023 | Shaun R. Bagai Chief Executive Officer | 520.0K | 69.4K | — | 349.7K | — | — | 936.8K | 37.33% | ↗ |
| 8 | 2023 | Ramtin Agah, M.D. Chief Medical Officer | — | 29.4K | — | 174.9K | — | 303.5K | 506.8K | 34.51% | ↗ |
| 9 | 2022 | Shaun R. Bagai Chief Executive Officer | 495.0K | — | — | 123.3K | 222.8K | — | 841.1K | 14.66% | ↗ |
| 10 | 2022 | Angela Gill Nelms Chief Operating Officer | 115.2K | — | — | 535.7K | 35.9K | 20.5K | 707.3K | 75.75% | ↗ |
| 11 | 2022 | Ramtin Agah, M.D. Chief Medical Officer | 289.0K | — | — | 54.6K | 91.0K | — | 434.7K | 12.57% | ↗ |
| 12 | 2021 | Shaun R. Bagai Chief Executive Officer | 322.8K | 160.0K | — | 504.9K | — | — | 987.8K | 51.12% | ↗ |
| 13 | 2021 | Ramtin Agah, M.D. Chief Medical Officer | 166.7K | 50.0K | — | 223.6K | — | — | 440.3K | 50.79% | ↗ |
| 14 | 2021 | Paul Manners Former Vice President, Finance and Principal Financial Officer | 160.7K | — | — | — | — | — | 160.7K | 0.00% | ↗ |
| 15 | 2021 | Christopher J. Lehman Chief Financial Officer | 129.7K | — | — | — | — | — | 129.7K | 0.00% | ↗ |
| 16 | 2020 | Shaun R. Bagai Chief Executive Officer | 253.0K | — | — | — | — | — | 253.0K | 0.00% | ↗ |
| 17 | 2020 | Ramtin Agah, M.D. Chief Medical Officer | 120.2K | — | — | — | — | — | 120.2K | 0.00% | ↗ |
| 18 | 2020 | Paul Manners Former Vice President, Finance and Principal Financial Officer | 43.4K | — | — | 7.0K | — | — | 50.5K | 13.93% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Shaun R. Bagai | Chief Executive Officer, Secretary & Director | 814.3K | male |
| Leesa Gentry | Chief Clinical Officer | 532.6K | female |
| Ramtin Agah | Founder, Executive Chairman & Chief Medical Officer | 432.7K | — |
| Ryan Witt | Senior Vice President and Head of Corporate Strategy & Partnerships | — | male |
| Robert Strasser | Vice President of Operations and R&D | — | male |
| Mark Voll | CFO & Principal Accounting Officer | — | male |
| Ronald Kocak | VP of Finance & Controller | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RNXT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
